The Expression and Significance of Serum Caveolin-1 in Patients with Kawasaki Disease

Feng Zhu ； Jing Huang ； Xuliang Wang ； Ping Li ； Yaoyao Yan ； Yunyun Zheng ； Yue'e He ； Tingting Wu ； Yue Ren ； Rongzhou Wu

《The Chinese Journal of Physiology》 63卷2期 (2020/04) Pp. 90-94

https://doi.org/10.4103/CJP.CJP_71_19

摘要

We investigated the expression of caveolin-1 (Cav-1) in Kawasaki disease (KD) and analyzed its relationship with coronary artery lesions (CALs). Cav-1 participated in the progression of CAL in KD. A total of 68 children with KD (23 with CALs), age matched with a fever control group (F, n = 28) and a normal control group (N, n = 24) were enrolled in this study. Cav-1 expression was detected using an enzyme-linked immunosorbent assay. The results are the following: (1) Compared with the F and N, Cav-1 expression was significantly increased in the children with KD (P ＜ 0.05); there was no significant difference in Cav-1 between the F and N. (2) The serum level of Cav-1 was significantly higher in children with KD and CALs during the acute phase than in children with KD without CALs (P ＜ 0.05). (3) Serum Cav-1 may be a biomarker that reflects CALs in children with KD based on a receiver operating characteristic (ROC) curve analysis. (4) Those children with KD who were given intravenous immunoglobulin (2 g/kg, 10-12 h) during the acute phase showed decreased expression of Cav-1 compared to the N. Conclusions are as follows: (1) The serum level of Cav-1 during the acute phase of KD increased significantly, while in KD patients with CALs the increase was even greater. (2) Based on our ROC curve analysis, Cav-1 may be a predictor of CALs in children with KD.

關鍵字

Caveolin-1 ； coronary artery lesions ； intravenous immunoglobulin ； Kawasaki disease

參考文獻

Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Pediatrics 2004;114:1708-33.

Falcini F, Capannini S, Rigante D. Kawasaki syndrome: An intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J 2011;9:17.

Shulman ST. IVGG therapy in Kawasaki disease: Mechanism(s) of action. Clin Immunol Immunopathol 1989;53:S141-6.

Hu G, Ye RD, Dinauer MC, Malik AB, Minshall RD. Neutrophil caveolin‑1 expression contributes to mechanism of lung inflammation and injury. Am J Physiol Lung Cell Mol Physiol 2008;294:L178-86.

Voghel G, Thorin-Trescases N, Farhat N, Nguyen A, Villeneuve L, Mamarbachi AM, et al. Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors. Mech Ageing Dev 2007;128:662-71.